Iterum Therapeutics Files 8-K with Material Agreement
Ticker: ITRM · Form: 8-K · Filed: Apr 30, 2025 · CIK: 1659323
| Field | Detail |
|---|---|
| Company | Iterum Therapeutics PLC (ITRM) |
| Form Type | 8-K |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Iterum Therapeutics signed a big deal on 4/28, filed 8-K on 4/30.
AI Summary
On April 28, 2025, Iterum Therapeutics plc entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The filing was made on April 30, 2025.
Why It Matters
This filing indicates a significant development for Iterum Therapeutics, likely involving a new contract or partnership that could impact its business operations and future prospects.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this summary filing.
Key Players & Entities
- Iterum Therapeutics plc (company) — Registrant
- April 28, 2025 (date) — Date of Earliest Event Reported
- April 30, 2025 (date) — Filing Date
FAQ
What is the nature of the material definitive agreement entered into by Iterum Therapeutics plc?
The filing does not specify the details of the material definitive agreement, only that one was entered into on April 28, 2025.
What other events are reported in this 8-K filing?
The filing indicates 'Other Events' were reported, but the specifics are not detailed in the provided text.
When was this 8-K form filed with the SEC?
The 8-K form was filed on April 30, 2025.
What is Iterum Therapeutics plc's principal executive office address?
Iterum Therapeutics plc's principal executive offices are located at 3 Dublin Landings, North Wall Quay, Dublin 1, Ireland.
What is Iterum Therapeutics plc's fiscal year end?
Iterum Therapeutics plc's fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 30, 2025 regarding Iterum Therapeutics plc (ITRM).